ZyStor Therapeutics, Inc. Cleared To Begin Clinical Trial For Targeted Protein Therapeutic For The Treatment Of Pompe Disease

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company’s proprietary Glycosylation Independent Lysosomal Targeting technology, announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

source : www.medicalnewstoday.com

Related News:

• Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders
• Kidney Cancer Drug Shows Promising Results
• Launch Of Ipsen’s Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
• Clinic Closure Leaves Indigent Dialysis Patients Looking For Treatment
• Launch Of Ipsen’s Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Advanced Or Metastatic Hormone-Dependent Prostate Cancer
• Household Pesticides Contaminate Storm Runoff And Sewage Treatment Outflow
• Recordati : Silodosin Approved By The European Commission For The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia
• Auxilium Announces U.S. Food And Drug Administration Approval For XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
• Two Studies Find Artefill(R) To Be A Long-Term Treatment Option For Facial Lipoatrophy
• New Treatment For Chronic Pain Condition

Details :
Submited at Saturday, October 17th, 2009 at 12:01 pm on Endocrinology by hilman
Comment RSS 2.0 - leave a comment - trackback